Home / Peptides / Peptides for Women

Peptides for Women: Which Ones Have Evidence, Which Don't, and What Changes by Life Stage

For women, the peptides with human evidence are the FDA-approved ones: bremelanotide for low desire, GLP-1 drugs for weight, and collagen peptides for bone. Research chemicals like BPC-157 have no data in women and no reproductive-safety data.

M
Written by
B.Sc. (Hons) Chemistry, MBA Pharma Mgmt (Pursuing) · Scientific Content Writer, Strong Health
D
Medically reviewed by
M.D., Board-Certified Psychiatrist · Medical Reviewer, Strong Health
Published: July 23, 2026 Updated: November 3, 2026 · Editorial Standards
12 min read

Key takeaways

  • Approved medications and oral collagen supplements are different categories; evidence must match the exact product, indication and life stage.
  • Compounding access is product-specific; conditional enforcement discretion does not establish FDA approval or treatment benefit.[90][91]
  • Growth hormone secretagogues work differently in women: women maintain greater GHRH potency and GHRP efficacy than men, and estradiol predicts the response.[8]
  • Tirzepatide lowers oral contraceptive exposure by roughly 20% after a single 5 mg dose; use a non-oral or barrier method for four weeks after starting and after each dose increase.[11]
  • In a 12-month trial of 131 postmenopausal women, 5 g/day of specific collagen peptides increased bone mineral density at the spine and femoral neck versus placebo.[5]

Most articles about peptides for women take a list of compounds studied mainly in men, add the word "women" to the headline, and change nothing else. That is the central problem with this category, and it is worth stating plainly before anything else. For the corresponding evidence review in men, see our guide to peptides for men.

Peptides are not a treatment. They are a class of molecule, short chains of amino acids, generally under 50 residues. Insulin is a peptide. So is semaglutide. So is the collagen powder in your cabinet, and so is a vial of unapproved research chemical shipped from an overseas lab. Grouping them under one banner and asking "are peptides good for women?" is like asking whether pills work.

The useful question is narrower: for a specific compound, in women, at what life stage, what does the evidence show, and is it legal to obtain? The answers vary enormously.

Which peptides have evidence in women, and which don't?

Peptides offered to women fall into three evidence tiers: FDA-approved drugs tested in women (bremelanotide, semaglutide, tirzepatide, liraglutide, tesamorelin, teriparatide), compounded preparations with variable evidence, and research chemicals with essentially no human data in women (BPC-157, TB-500, Epitalon, MOTS-c). Every peptide a clinic might offer you falls into one of these three categories. Knowing which tier a compound sits in tells you more about your actual risk than any benefit claim on the clinic's website.

Tier What it means Examples Evidence quality
FDA-approved drugs Went through full clinical trials. Known dose, known label, known adverse events, manufacturer liability. Bremelanotide (Vyleesi), semaglutide, tirzepatide, liraglutide, tesamorelin (Egrifta), teriparatide Strong to moderate, with published trial data
Compounded preparations Made by a licensed pharmacy against an individual prescription. Legality depends on a specific FDA list. Sermorelin, some GH-releasing analogs Variable; often extrapolated from small studies
Research chemicals Sold "for research use only." No FDA oversight of purity, dose, or sterility. BPC-157, TB-500, Epitalon, Melanotan II, and most of what circulates online Weak; largely rodent data or none

The third tier is where the marketing is loudest and the evidence is thinnest. It is also where sex-specific data is essentially nonexistent.

What is the current compounding context?

Compounding access is specific to the substance, route and current federal and state requirements. The October 2026 HHS policy describes conditional enforcement discretion for six specified substances under section 503A; it is not FDA approval or a finding of effectiveness. It does not establish blanket 503B access. Review the exact proposed product with the prescriber and pharmacist.[90][91]

Availability, FDA approval and evidence of benefit are separate questions. A clinician should explain the approved indication, any proposed off-label use, the human evidence and the remaining uncertainties. Do not infer that a general peptide policy covers the exact product being advertised.

How does being a woman change the peptide evidence?

Being a woman changes the peptide evidence in three ways. Women are underrepresented in the underlying research, growth hormone secretagogues produce measurably different responses in women than in men, and life stage (fertility, pregnancy, lactation, menopause) changes the risk calculation for every compound. This is the part most content on this topic skips, and it is the part that matters.

Women are underrepresented in the underlying research

The problem starts before human trials. Preclinical work still does not consistently include female animals, and when it does, the results often are not reported separately by sex. Even in areas with mandated mixed-sex enrollment, published analyses frequently fail to break out sex-specific findings. For GLP-1 analogs specifically, safety and pharmacokinetic studies have tended to exclude female subjects.[7]

This is not a minor gap. Women have roughly 1.5 to 1.7 times the risk of adverse drug reactions in some drug classes, and dosing guidelines often ignore known sex differences in drug metabolism. When a peptide's entire evidence base is male rodents, "we don't know how this behaves in a 52-year-old woman" is the honest summary.

Growth hormone secretagogues behave differently in women

This is one of the few areas with real sex-comparison data, and it complicates the standard clinic pitch.

Research from the Mayo Clinic endocrine group found that women maintain greater GHRH potency and greater GHRP efficacy than men, with different opposing somatostatin output.

“The current outcomes suggest that women maintain greater GHRH potency, GHRP efficacy, and opposing SS outflow than men.”

Veldhuis JD, et al., dual-secretagogue study in eight men and six women, Journal of Clinical Endocrinology & Metabolism, 2005 — PubMed

Estradiol levels positively predicted the response to one secretagogue combination, while testosterone negatively predicted the response to another.[8] In separate work in older adults, recovery of GH secretion after feedback suppression depended on sex, on sex-steroid status, and on which class of peptide was used, and those factors interacted rather than adding up neatly.[9]

The practical implication: a woman's response to a GH secretagogue is likely modulated by where she sits in the menopausal transition and whether she is on hormone therapy. A protocol designed around male physiology is not a protocol designed for her. Very few clinics account for this. Our overview of peptides in an anti-aging context covers how these secretagogues work in more depth.

Life stage changes the risk calculation entirely

Perimenopause, pregnancy, lactation, and postmenopause are different physiological states with different risks. A compound with no reproductive toxicity data is a very different proposition for a 34-year-old who might conceive than for a 64-year-old who will not.

How does each peptide stack up for women?

Bremelanotide (Vyleesi): FDA-approved, modest effect

This is the one peptide approved specifically for a female indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women, approved in 2019.[2] Bremelanotide is a melanocortin receptor agonist acting centrally rather than on blood flow, given by autoinjector as needed before anticipated activity. We cover the same molecule from a mechanism angle in our guide to peptides for libido.

The efficacy is real but small, and the FDA's own summary is more sober than most clinic pages. Across two 24-week randomized, placebo-controlled trials in 1,247 premenopausal women, about 25% of treated patients had a meaningful increase in desire score compared with about 17% on placebo. About 35% had a meaningful decrease in distress score versus about 31% on placebo. There was no difference between groups in the number of satisfying sexual events.[1][4]

Nausea is common. It raises blood pressure transiently, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease, and not recommended in those at high cardiovascular risk. It can also cause skin hyperpigmentation through MC1R activity.[1]

If low desire is the concern, it is worth ruling out the common drivers first (thyroid dysfunction, antidepressants, relationship factors, sleep debt, genitourinary syndrome of menopause) before reaching for a drug with a single-digit absolute benefit over placebo.

GLP-1 and dual agonists: strong evidence, real women-specific caveats

Semaglutide, liraglutide, and tirzepatide are peptides, and they have the best evidence in this entire article. Several caveats apply specifically to women and are routinely missed. For the general picture, see our guide to peptides for weight loss.

  • •Oral contraceptive interaction. Tirzepatide reduces oral contraceptive absorption by delaying gastric emptying. The label documents roughly a 20% reduction in ethinyl estradiol and norgestimate exposure after a single 5 mg dose, with greater reductions following escalation. The manufacturer recommends switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Semaglutide, liraglutide, and dulaglutide do not appear to meaningfully affect oral contraceptive bioavailability. IUDs, implants, injections, patches, and rings bypass the issue entirely.[10][11]
  • •Returning fertility. In women with PCOS or obesity-related anovulation, weight loss frequently restores ovulation. A woman who has considered herself infertile for years can become fertile without warning. Combine that with a contraceptive absorption issue and you have the mechanism behind most unplanned pregnancies on these drugs.
  • •Preconception washout. The Wegovy label recommends discontinuing at least two months before a planned pregnancy, based on semaglutide's roughly seven-day half-life and limited human pregnancy data. Similar timing is generally applied to tirzepatide.[12]
  • •PCOS. Off-label use has reasonable support. In one 12-week randomized trial in obese women with PCOS, liraglutide outperformed metformin on weight, BMI, and waist circumference. Larger trials have shown menstrual regularity returning in a substantial share of responders.[13]
  • •Bone and lean mass. Rapid weight loss costs lean mass and bone density, and postmenopausal women are already losing bone from estrogen withdrawal. Resistance training, adequate protein, and a baseline DEXA scan are not optional extras here.

Collagen peptides: the best female-specific evidence, with a caveat

Oral collagen peptides are food-grade supplements, not injections, and they have been studied in women more rigorously than almost anything else in this space.

The strongest trial randomized 131 postmenopausal women with age-related bone loss to 5 g/day of specific collagen peptides or placebo for 12 months, measuring bone mineral density at the femoral neck and spine by DEXA along with bone turnover markers. It found improvements in BMD and favorable shifts in P1NP and CTX-1.[5]

The caveat matters: that study was co-authored by researchers affiliated with a collagen research institute, and industry funding is the norm across this literature. Independent replication is thinner than the marketing suggests.

Results are also not uniform. A 2025 randomized trial in menopausal women testing fish-derived collagen with and without calcium and vitamin D over six months found no significant changes in body composition or bone biomarkers, though skin elasticity and hydration did improve and hair shedding was reduced relative to placebo.[6]

Reasonable read: modest, real benefits for skin, plausible benefit for bone that needs better independent data, low risk, low cost.

Tesamorelin: approved, but for a narrow indication

A GHRH analog approved for HIV-associated lipodystrophy. Trial data exists in both sexes. Its approved use is specific, and off-label use for general body composition in healthy women is not supported by comparable evidence.

BPC-157, TB-500, Epitalon, MOTS-c, and the rest

These are the compounds driving most peptide search traffic, and I am going to be blunt: for women specifically, the human evidence is close to nonexistent.

BPC-157 has no completed human randomized controlled trials. Neither does TB-500. Full thymosin beta-4 has some trial history, including a Phase 2 dry eye program that missed its endpoints. The claims about tissue repair come mainly from rodent studies, many with methodological problems. There is no meaningful female-specific safety data, no reproductive toxicity data, and no long-term follow-up.

I am not going to provide dosing or sourcing information for these. Not out of squeamishness: there is no dose I could give you that would be evidence-based, and pretending otherwise would be dishonest.

Melanotan II: worth a specific warning

Frequently marketed to women for tanning. It is a nonselective melanocortin agonist associated with nausea, blood pressure changes, and, notably, changes to existing moles and new pigmented lesions. Case reports describe melanoma diagnosed in users. Dermatologists have flagged this repeatedly. Not worth it.

What safety questions should women ask before using peptides?

  • •Pregnancy and lactation. Almost no peptide in the non-approved tiers has reproductive toxicity data. For approved GLP-1s, the guidance is a defined washout before conception. For everything else, the honest answer is that nobody knows, which should be treated as a stop, not a shrug.
  • •Thyroid history. GLP-1 and dual agonists carry a boxed warning regarding thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2.
  • •Cardiovascular history. Bremelanotide is contraindicated in uncontrolled hypertension and known cardiovascular disease.
  • •Breast and gynecologic cancer history. Anything that raises IGF-1 deserves an explicit conversation with your oncologist. GH secretagogues work by increasing GH and, downstream, IGF-1.
  • •Bone density. If you are postmenopausal and pursuing significant weight loss, get a baseline DEXA scan.
  • •Hormone therapy interactions. If you are on estrogen therapy, that changes GH secretagogue response, per the sex-steroid research above. Your prescriber should know.

What should you ask a peptide clinic?

  1. Is this compound FDA-approved for anything? If not, is it currently on the 503A bulks list?
  2. Where is it made, and can I see a certificate of analysis from an accredited third-party lab?
  3. What human trials exist in women, not men or rodents?
  4. What baseline labs will you run, and what will you recheck?
  5. What would make you stop treatment?
  6. What is the plan if I want to become pregnant?
  7. Do you have a financial relationship with the pharmacy dispensing this?

A clinic that answers these directly is a different proposition from one that redirects to testimonials. You can browse every protocol we discuss in our peptide therapy hub.

The short version: which peptides are worth it for women?

Peptides that went through FDA approval have real, measurable, and often modest effects, with documented risks and women-specific precautions worth taking seriously. Peptides sold as research chemicals have loud marketing, thin evidence, no quality control, and essentially no data in women. The regulatory status of the middle group is actively changing this month, and anyone who tells you it is settled has not checked.

If a clinic cannot tell you which tier a compound is in, that is your answer.

Frequently Asked Questions

Are peptides safe for women?
It depends entirely on which peptide. FDA-approved peptide drugs have known safety profiles established in trials that included women. Unapproved research chemicals have no safety profile in women at all, and no reproductive toxicity data. The category label tells you nothing useful. The specific compound and your life stage are what determine risk.
Can I take peptides while trying to conceive?
For GLP-1 medications, labeling recommends discontinuing at least two months before a planned pregnancy. For unapproved peptides, there is no safety data in pregnancy, so the appropriate answer is no. Always discuss preconception planning with your OB-GYN before starting or stopping any peptide.
Do peptides affect birth control?
Tirzepatide reduces oral contraceptive absorption, and the label recommends backup or non-oral contraception for four weeks after starting and after each dose increase. Semaglutide and liraglutide do not appear to have a clinically meaningful effect. Non-oral methods (IUDs, implants, injections, patches, and rings) are unaffected.
Is BPC-157 legal in 2026?
Compounding is substance- and route-specific. The October 2026 HHS policy describes conditional enforcement discretion for six specified substances under section 503A. It does not establish FDA approval, effectiveness or blanket 503B access. Your clinician and pharmacist should confirm current federal and state requirements for the exact proposed product.
Do peptides help with menopause symptoms?
No peptide is FDA-approved for vasomotor symptoms. Oral collagen peptides have modest evidence for skin and mixed evidence for bone in menopausal women. For hot flashes, night sweats, and genitourinary symptoms, hormone therapy and approved non-hormonal options have far better evidence.
Will peptides help me lose weight?
GLP-1 and dual agonist medications such as semaglutide and tirzepatide have strong trial evidence for weight loss. Growth hormone secretagogues marketed for fat loss do not have comparable evidence in healthy women, and rapid weight loss also costs lean mass and bone density, which matters more after menopause.
Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Authorship and review information are shown where recorded; an editorial update is not a new medical review.

Related Articles

Molecules in this guide

Browse the molecule library →

Compare the research, safety questions and regulatory context for each molecule. Inclusion in this guide does not establish effectiveness or treatment availability.

Looking for care? View Strong Health locations and visit options.

Considering Peptide Therapy? Talk to a Physician First.

Our physicians review your history, labs, and life stage (including pregnancy plans and hormone therapy) and will tell you plainly which tier a compound sits in and whether the evidence supports it for you.

References & Citations

  1. U.S. FDA. VYLEESI (bremelanotide injection) prescribing information. accessdata.fda.gov.
  2. U.S. FDA. News release: FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women, June 21, 2019.
  3. U.S. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A; update of April 15, 2026. Docket FDA-2025-N-6895.
  4. Simon JA, et al. Bremelanotide for hypoactive sexual desire disorder (RECONNECT trials). Obstetrics & Gynecology, 2019.
  5. König D, Oesser S, Scharla S, Zdzieblik D, Gollhofer A. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women — a randomized controlled study. Nutrients. 2018;10(1):97.
  6. Calcium and vitamin D supplementation with and without collagen on bone density and skin elasticity in menopausal women — a randomized controlled study. Clinics and Practice. 2025;15(9):168.
  7. GLP-1 and its analogs: does sex matter? Endocrinology. 2025;166(2):bqae165.
  8. Veldhuis JD, et al. Complementary secretagogue pairs unmask gender-related contrasts in growth hormone pulse renewal. PMID 15634714.
  9. Veldhuis JD, et al. Gender, sex-steroid, and secretagogue-selective recovery from growth hormone-induced feedback in older women and men. PMID 21613353.
  10. Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and GLP-1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc. 2024;64(1):204-211.
  11. Mounjaro (tirzepatide) prescribing information, Eli Lilly.
  12. Wegovy (semaglutide) prescribing information, Novo Nordisk.
  13. Jensterle M, et al. Short-term monotherapy with liraglutide or roflumilast is superior to metformin in weight loss in obese PCOS women.
  14. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020.
  15. FDA. Human Drug Compounding. Accessed November 3, 2026.
  16. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. October 2026; accessed November 3, 2026.
👉 Book a Free Peptide Therapy Assessment